Oral immunotherapy for peanut allergy ‘increases risk’
There is 'significant uncertainty' over the experimental treatment's long-term safety and efficacy, say experts
Oral immunotherapy for peanut allergy greatly increases the risk of life-threatening anaphylactic reactions rather than preventing them as intended, a review of trials has found.
And despite achieving the immunological goal of desensitisation, the experimental treatment failed to improve quality of life compared with the standard of care, the researchers say.
